Published in Proc Natl Acad Sci U S A on February 18, 2010
Kinesins and cancer. Nat Rev Cancer (2012) 1.84
Killing cells by targeting mitosis. Cell Death Differ (2012) 1.65
Mitosis-targeted anti-cancer therapies: where they stand. Cell Death Dis (2012) 1.60
Using transcriptome sequencing to identify mechanisms of drug action and resistance. Nat Chem Biol (2012) 1.53
Acetylation of Aurora B by TIP60 ensures accurate chromosomal segregation. Nat Chem Biol (2016) 1.45
Uncoordinated loss of chromatid cohesion is a common outcome of extended metaphase arrest. PLoS One (2011) 1.45
Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast Cancer Res (2016) 1.38
Bub1 and BubR1: at the interface between chromosome attachment and the spindle checkpoint. Mol Cell Biol (2011) 1.29
Chromosome missegregation rate predicts whether aneuploidy will promote or suppress tumors. Proc Natl Acad Sci U S A (2013) 1.28
Aurora A Kinase Contributes to a Pole-Based Error Correction Pathway. Curr Biol (2015) 1.28
CLASPs prevent irreversible multipolarity by ensuring spindle-pole resistance to traction forces during chromosome alignment. Nat Cell Biol (2012) 1.27
Kinetochore kinesin CENP-E is a processive bi-directional tracker of dynamic microtubule tips. Nat Cell Biol (2013) 1.27
Aneuploidy generates proteotoxic stress and DNA damage concurrently with p53-mediated post-mitotic apoptosis in SAC-impaired cells. Nat Commun (2015) 1.11
Lateral to end-on conversion of chromosome-microtubule attachment requires kinesins CENP-E and MCAK. Curr Biol (2013) 1.10
Cancer-Specific requirement for BUB1B/BUBR1 in human brain tumor isolates and genetically transformed cells. Cancer Discov (2012) 1.07
Force generation by kinesin and myosin cytoskeletal motor proteins. J Cell Sci (2013) 1.05
Prognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinoma. Mol Cancer (2010) 1.04
Loop L5 acts as a conformational latch in the mitotic kinesin Eg5. J Biol Chem (2010) 1.02
Probing CENP-E function in chromosome dynamics using small molecule inhibitor syntelin. Cell Res (2010) 0.98
A role for histone H4K16 hypoacetylation in Saccharomyces cerevisiae kinetochore function. Genetics (2011) 0.97
Cell death signaling and anticancer therapy. Front Oncol (2011) 0.91
A myosin V inhibitor based on privileged chemical scaffolds. Angew Chem Int Ed Engl (2010) 0.91
Adaptive changes in the kinetochore architecture facilitate proper spindle assembly. Nat Cell Biol (2015) 0.91
A screen for kinetochore-microtubule interaction inhibitors identifies novel antitubulin compounds. PLoS One (2010) 0.90
The spindle and kinetochore-associated (Ska) complex enhances binding of the anaphase-promoting complex/cyclosome (APC/C) to chromosomes and promotes mitotic exit. Mol Biol Cell (2014) 0.90
Mitosis as an anti-cancer drug target. Chromosoma (2013) 0.88
Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 0.87
Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715. Mol Cancer Ther (2013) 0.87
Loop 5-directed compounds inhibit chimeric kinesin-5 motors: implications for conserved allosteric mechanisms. J Biol Chem (2010) 0.84
Hitting the brakes: targeting microtubule motors in cancer. Br J Cancer (2015) 0.83
Mechanisms of Chromosome Congression during Mitosis. Biology (Basel) (2017) 0.82
Optogenetic control of kinetochore function. Nat Chem Biol (2017) 0.82
Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition. Int J Cancer (2012) 0.81
Unliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpoint. Breast Cancer Res Treat (2011) 0.81
Kinetochore-microtubule attachment throughout mitosis potentiated by the elongated stalk of the kinetochore kinesin CENP-E. Mol Biol Cell (2014) 0.80
Germline mutations causing familial lung cancer. J Hum Genet (2015) 0.79
Small molecule screen for candidate antimalarials targeting Plasmodium Kinesin-5. J Biol Chem (2014) 0.79
High rates of chromosome missegregation suppress tumor progression but do not inhibit tumor initiation. Mol Biol Cell (2016) 0.78
Cenp-E inhibitor GSK923295: Novel synthetic route and use as a tool to generate aneuploidy. Oncotarget (2015) 0.78
Dynein light intermediate chains maintain spindle bipolarity by functioning in centriole cohesion. J Cell Biol (2014) 0.78
Downregulation of miR-137 and miR-6500-3p promotes cell proliferation in pediatric high-grade gliomas. Oncotarget (2016) 0.77
Targeting a kinetochore-associated motor protein to kill cancer cells. Proc Natl Acad Sci U S A (2010) 0.77
Overexpression of the dynein light chain km23-1 in human ovarian carcinoma cells inhibits tumor formation in vivo and causes mitotic delay at prometaphase/metaphase. Int J Cancer (2011) 0.77
Chromosome congression is promoted by CENP-Q- and CENP-E-dependent pathways. J Cell Sci (2014) 0.76
A Novel Time-Dependent CENP-E Inhibitor with Potent Antitumor Activity. PLoS One (2015) 0.76
Examining the mechanism of action of a kinesin inhibitor using stable isotope labeled inhibitors for cross-linking (SILIC). J Am Chem Soc (2011) 0.76
XAB2 functions in mitotic cell cycle progression via transcriptional regulation of CENPE. Cell Death Dis (2016) 0.76
Kalanchoe tubiflora extract inhibits cell proliferation by affecting the mitotic apparatus. BMC Complement Altern Med (2012) 0.76
Kinesin Motor Enzymology: Chemistry, Structure, and Physics of Nanoscale Molecular Machines. Biophys Rev (2015) 0.75
Motor activity of centromere-associated protein-E contributes to its localization at the center of the midbody to regulate cytokinetic abscission. Oncotarget (2016) 0.75
Recent findings and future directions for interpolar mitotic kinesin inhibitors in cancer therapy. Future Med Chem (2016) 0.75
Inhibition of Bcl-xL sensitizes cells to mitotic blockers, but not mitotic drivers. Open Biol (2016) 0.75
Discovery of Novel Allosteric Eg5 Inhibitors Through Structure-Based Virtual Screening. Chem Biol Drug Des (2016) 0.75
Spindle assembly checkpoint satisfaction occurs via end-on but not lateral attachments under tension. J Cell Biol (2017) 0.75
Spindle assembly checkpoint signaling and sister chromatid cohesion are disrupted by HPV E6-mediated transformation. Mol Biol Cell (2017) 0.75
Targeting mitotic pathways for endocrine-related cancer therapeutics. Endocr Relat Cancer (2017) 0.75
Development and validation of a genetic algorithm for flexible docking. J Mol Biol (1997) 14.36
The way things move: looking under the hood of molecular motor proteins. Science (2000) 7.28
Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell (2008) 6.62
Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell (2006) 6.37
Mad2-Independent inhibition of APCCdc20 by the mitotic checkpoint protein BubR1. Dev Cell (2001) 5.82
CENP-E is a putative kinetochore motor that accumulates just before mitosis. Nature (1992) 5.54
Chromosomes can congress to the metaphase plate before biorientation. Science (2006) 4.64
Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds the cyclosome/APC. J Cell Biol (1999) 4.15
CENP-E forms a link between attachment of spindle microtubules to kinetochores and the mitotic checkpoint. Nat Cell Biol (2000) 3.96
CENP-E function at kinetochores is essential for chromosome alignment. J Cell Biol (1997) 3.49
Pathway of processive ATP hydrolysis by kinesin. Nature (1995) 3.46
Unattached kinetochores catalyze production of an anaphase inhibitor that requires a Mad2 template to prime Cdc20 for BubR1 binding. Dev Cell (2009) 3.36
Centromere-associated protein-E is essential for the mammalian mitotic checkpoint to prevent aneuploidy due to single chromosome loss. J Cell Biol (2003) 3.15
CENP-E is essential for reliable bioriented spindle attachment, but chromosome alignment can be achieved via redundant mechanisms in mammalian cells. Mol Biol Cell (2001) 3.13
Characterization of the kinetochore binding domain of CENP-E reveals interactions with the kinetochore proteins CENP-F and hBUBR1. J Cell Biol (1998) 3.11
BubR1 N terminus acts as a soluble inhibitor of cyclin B degradation by APC/C(Cdc20) in interphase. Dev Cell (2009) 2.69
A processive single-headed motor: kinesin superfamily protein KIF1A. Science (1999) 2.64
Activating and silencing the mitotic checkpoint through CENP-E-dependent activation/inactivation of BubR1. Cell (2003) 2.47
Microtubule capture by CENP-E silences BubR1-dependent mitotic checkpoint signaling. J Cell Biol (2005) 2.11
Pathway of ATP hydrolysis by monomeric and dimeric kinesin. Biochemistry (1998) 2.01
Antitumor activity of a kinesin inhibitor. Cancer Res (2004) 1.93
CENP-E combines a slow, processive motor and a flexible coiled coil to produce an essential motile kinetochore tether. J Cell Biol (2008) 1.77
15 A resolution model of the monomeric kinesin motor, KIF1A. Cell (2000) 1.76
Gene silencing of CENP-E by small interfering RNA in HeLa cells leads to missegregation of chromosomes after a mitotic delay. Mol Biol Cell (2004) 1.73
A structural pathway for activation of the kinesin motor ATPase. EMBO J (2001) 1.64
Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate. Mol Cancer Ther (2008) 1.53
Interaction of the mitotic inhibitor monastrol with human kinesin Eg5. Biochemistry (2003) 1.51
Mechanism of inhibition of human KSP by ispinesib. Biochemistry (2008) 1.21
Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP. Bioorg Med Chem Lett (2005) 1.19
Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res (2009) 1.13
Crystal structure of the motor domain of the human kinetochore protein CENP-E. J Mol Biol (2004) 1.04
Centromere-associated protein E: a motor that puts the brakes on the mitotic checkpoint. Clin Cancer Res (2008) 1.03
Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295. ACS Med Chem Lett (2010) 0.88
ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell (2005) 7.65
Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. Neuron (2004) 7.48
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature (2012) 7.01
A critical assessment of docking programs and scoring functions. J Med Chem (2006) 5.78
Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. Methods Biochem Anal (2005) 5.37
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature (2011) 5.32
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A (2010) 4.52
Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science (2011) 4.36
ROCK-generated contractility regulates breast epithelial cell differentiation in response to the physical properties of a three-dimensional collagen matrix. J Cell Biol (2003) 4.24
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20
Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer (2007) 4.16
An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother (2011) 4.02
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol (2012) 3.89
GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res (2011) 3.36
Nutrient metal sequestration by calprotectin inhibits bacterial superoxide defense, enhancing neutrophil killing of Staphylococcus aureus. Cell Host Microbe (2011) 2.66
Chromatin proteins and modifications as drug targets. Nature (2013) 2.60
Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry (2008) 2.47
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood (2013) 2.28
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A (2013) 2.26
Src phosphorylation of cortactin enhances actin assembly. Proc Natl Acad Sci U S A (2007) 2.16
Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res (2008) 2.15
Phosphorylation by cyclin B-Cdk underlies release of mitotic exit activator Cdc14 from the nucleolus. Science (2004) 2.14
EMT is the dominant program in human colon cancer. BMC Med Genomics (2011) 2.05
A mechanism for microtubule depolymerization by KinI kinesins. Mol Cell (2002) 1.95
Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev (2003) 1.95
Antitumor activity of a kinesin inhibitor. Cancer Res (2004) 1.93
Aggrecan protects cartilage collagen from proteolytic cleavage. J Biol Chem (2003) 1.93
Molecular shape and medicinal chemistry: a perspective. J Med Chem (2010) 1.91
Hydrophilic interaction chromatography reduces the complexity of the phosphoproteome and improves global phosphopeptide isolation and detection. Mol Cell Proteomics (2008) 1.88
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood (2012) 1.81
Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res (2005) 1.80
Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med (2012) 1.79
Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem J (2008) 1.79
Chemogenetic analysis of human protein methyltransferases. Chem Biol Drug Des (2011) 1.77
Yersiniabactin synthetase: a four-protein assembly line producing the nonribosomal peptide/polyketide hybrid siderophore of Yersinia pestis. Chem Biol (2002) 1.75
The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore. J Pharmacol Exp Ther (2002) 1.59
Nicolau Syndrome: three cases and review. Int J Dermatol (2006) 1.57
Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol (2005) 1.57
Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail (2010) 1.57
Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth. Cancer Biol Ther (2012) 1.56
Comparison of neosaxitoxin versus bupivacaine via port infiltration for postoperative analgesia following laparoscopic cholecystectomy: a randomized, double-blind trial. Reg Anesth Pain Med (2011) 1.54
New class of HIV-1 integrase (IN) inhibitors with a dual mode of action. J Biol Chem (2012) 1.52
Survival following primary surgery for oral cancer. Oral Oncol (2008) 1.50
The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS Lett (2011) 1.42
Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J Med Chem (2008) 1.41
Differential regulation of WASP and N-WASP by Cdc42, Rac1, Nck, and PI(4,5)P2. Biochemistry (2007) 1.40
ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism. Nat Chem Biol (2007) 1.39
A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues. Proc Natl Acad Sci U S A (2006) 1.38
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther (2014) 1.37
Structural basis for novel delta-regioselective heme oxygenation in the opportunistic pathogen Pseudomonas aeruginosa. Biochemistry (2004) 1.36
Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study. Anesthesiology (2003) 1.35
Structure of a kinesin microtubule depolymerization machine. EMBO J (2004) 1.34
Phosphorylation sites in BubR1 that regulate kinetochore attachment, tension, and mitotic exit. J Cell Biol (2008) 1.33
Mapping phosphorylation sites in proteins by mass spectrometry. Methods Enzymol (2002) 1.32
TULA: an SH3- and UBA-containing protein that binds to c-Cbl and ubiquitin. Oncogene (2004) 1.30
Dbf2-Mob1 drives relocalization of protein phosphatase Cdc14 to the cytoplasm during exit from mitosis. J Cell Biol (2009) 1.29
Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells. PLoS One (2013) 1.29
GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther (2009) 1.27
Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion (2005) 1.27
A ubiquitin-proteasome pathway represses the Drosophila immune deficiency signaling cascade. Curr Biol (2002) 1.26
Integrated analysis of breast cancer cell lines reveals unique signaling pathways. Genome Biol (2009) 1.25
Cdc5 influences phosphorylation of Net1 and disassembly of the RENT complex. BMC Mol Biol (2002) 1.24
Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models. Clin Cancer Res (2011) 1.23
Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes. Antimicrob Agents Chemother (2006) 1.22
Oleic acid and peanut oil high in oleic acid reverse the inhibitory effect of insulin production of the inflammatory cytokine TNF-alpha both in vitro and in vivo systems. Lipids Health Dis (2009) 1.21
Mechanism of inhibition of human KSP by ispinesib. Biochemistry (2008) 1.21
Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity. Mol Cancer Ther (2005) 1.20
Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models. Mol Cancer Ther (2012) 1.20
Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. Chem Biol (2011) 1.20
Insight into the molecular mechanism of the multitasking kinesin-8 motor. EMBO J (2010) 1.19
BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS One (2013) 1.19
Nuclear fusion occurs during mating in Candida albicans and is dependent on the KAR3 gene. Mol Microbiol (2005) 1.19
Druggability Assessment of Allosteric Proteins by Dynamics Simulations in the Presence of Probe Molecules. J Chem Theory Comput (2012) 1.18
Identification of novel SH3 domain ligands for the Src family kinase Hck. Wiskott-Aldrich syndrome protein (WASP), WASP-interacting protein (WIP), and ELMO1. J Biol Chem (2002) 1.18